IntriCon Corporation (IIN): Price and Financial Metrics

IIN Stock Price Chart Interactive Chart >

IIN Price/Volume Stats

IntriCon Corporation (IIN) Company Bio

IntriCon Corporation designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical bio-telemetry devices, hearing healthcare, and professional audio communication devices markets. The company also provides medical and micro coils for pacemaker programming and interventional catheter positioning applications; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers. In addition, it offers professional audio headset products used for emergency response needs in the fire, law enforcement, safety, aviation, and military markets; and a line of miniature ear-and head-worn devices used by performers and support staff in the music and stage performance markets. The company sells its hearing device products, and medical and professional audio communications products directly to hearing instrument manufacturers, distributors, and partnerships; and microphone products to the radio communication and professional audio industries, as well as markets and sells hearing aid devices directly to consumers through direct mail advertising, Internet, and call center. IntriCon Corporation was formerly known as Selas Corporation of America. The company was founded in 1930 and is based in Arden Hills, Minnesota.

IIN Price Forecast Based on DCF Valuation

We started the process of determining a valid price forecast for Intricon Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Intricon Corp ranked in the 15th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88%. In terms of the factors that were most noteworthy in this DCF analysis for IIN, they are:

• The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately merely 12.91% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
• As a business, Intricon Corp experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.

Want more companies with a valuation profile/forecast similar to that of Intricon Corp? See BHC, LCI, MD, PAHC, and TECH.